Panbela Therapeutics (PBLA)
OTHER OTC:PBLA
Top Page
No summary available
Positive Factors
Strategic Investment
This investment demonstrates confidence in Panbela's approach and provides crucial financial support, enabling continued R&D and clinical trials.
Negative Factors
Financial Instability
Ongoing financial losses highlight significant operational challenges and reliance on external funding, which may impact long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Investment
This investment demonstrates confidence in Panbela's approach and provides crucial financial support, enabling continued R&D and clinical trials.
Read all positive factors
Panbela Therapeutics (PBLA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$971.00
Dividend YieldN/A
Average Volume (3M)4.36K
Price to Earnings (P/E)―
Beta (1Y)132.69
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,854,831
10 Day Avg. Volume549
30 Day Avg. Volume4,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-12.14
Price to Sales (P/S)0.00
P/FCF Ratio-2.27
Enterprise Value/Market Cap2.70K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.09
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Panbela Therapeutics Business Overview & Revenue Model
Company Description
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, inclu...
How the Company Makes Money
Panbela Therapeutics generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company invests heavily in research and development to bring its innovations from the lab to the market. Potent...
Panbela Therapeutics Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -29.04M | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M |
| EBITDA | -26.40M | -51.29M | -34.74M | -10.61M | -5.05M | -4.42M |
| Net Income | -27.91M | -25.26M | -34.93M | -10.13M | -4.77M | -6.20M |
Balance Sheet | ||||||
| Total Assets | 5.17M | 11.80M | 4.98M | 12.87M | 9.81M | 3.14M |
| Cash, Cash Equivalents and Short-Term Investments | 142.00K | 2.58M | 1.28M | 11.87M | 9.02M | 2.45M |
| Total Debt | 6.39M | 5.19M | 6.84M | 0.00 | 0.00 | 116.00K |
| Total Liabilities | 23.34M | 16.51M | 13.03M | 2.66M | 1.36M | 1.76M |
| Stockholders Equity | -18.17M | -4.71M | -8.05M | 10.21M | 8.45M | 1.39M |
Cash Flow | ||||||
| Free Cash Flow | -15.57M | -25.25M | -15.94M | -6.70M | -3.85M | -2.74M |
| Operating Cash Flow | -15.57M | -25.25M | -15.28M | -6.70M | -3.85M | -2.74M |
| Investing Cash Flow | -7.97M | 400.00K | -656.00K | -540.00K | 0.00 | 0.00 |
| Financing Cash Flow | 14.03M | 26.14M | 5.35M | 10.10M | 10.44M | 3.78M |
Panbela Therapeutics Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.03
Negative
0.13
Negative
Market Momentum
>-0.01
Positive
45.82
Neutral
-0.04
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBLA, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.82 is Neutral, neither overbought nor oversold. The STOCH value of -0.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBLA.
Panbela Therapeutics Risk Analysis
Panbela Therapeutics disclosed 34 risk factors in its most recent earnings report. Panbela Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Panbela Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
PBLA
Panbela Therapeutics
0.01
-0.30
-96.49%
BDRX
Biodexa Pharmaceuticals
3.25
-69.75
-95.55%
QCLS
Q/C Technologies
3.70
-23.30
-86.30%
SCNI
Scinai Immunotherapeutics
0.59
-1.33
-69.22%
OGEN
Oragenics
0.66
-4.93
-88.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―